Search PubMed⌕ Search

Biomedical subjects

B Nägeli

Publications and source records attributed to B Nägeli.

2 recordsLinked to original sources

[Cardiogenic shock].

Cardiogenic shock (CS), defined as forward failure combined with systolic blood pressure < 90 mm Hg and reduced organ perfusion despite adequate volume loading, still has a grim prognosis with mortality rates of 80-100% if the causes are left untreated. The most frequent conditions underlying CS are acute myocardial infarction, acute and severe aortic or mitral incompetence, rapidly progressive dilatative cardiomyopathy and hypertrophic obstructive cardiomyopathy. Whereas correct conservative management by drugs and pacing may be life saving in the latter, the other conditions require early invasive management. Indications for cardiac surgery and circulatory assistance are given for mechanical complications leading to CS. In CS complicating myocardial infarction, comprehensive management with early invasive revascularization and intraaortic balloon pumping may result in improved survival compared with the disappointing outcome of medical treatment, including fibrinolysis. This strategy can be offered to the majority of infarct patients in CS, who are primarily admitted to hospitals not equipped for interventional cardiology or cardiac surgery. Between-hospital transfer of these patients for PTCA (or surgery) and advanced intensive care has been shown to be feasible and safe.

Hemodynamics↗

[Current pharmacotherapy of heart insufficiency in old age].

Signs of cardiovascular diseases have been found in more than 50% of elderly people over 65 years in industrialized countries. Congestive heart failure is an especially disabling consequence in up to 49% of the age-class 75 to 80 years. Treatment of these patients follows the same guidelines as in younger patients with congestive heart failure; however, treatment results are poor in many instances, and undesirable side effects are frequent. For an adequate management of congestive heart failure in the elderly, one should consider specific age-related changes of the heart muscle cell, of the myocardial structure, of the vessel wall as well as functional changes of cardiovascular regulation, e.g. blunted reflexes and disturbed feed-back loops of hormonal regulation. Moreover, pharmacokinetic and pharmacodynamic properties of medicaments differ in elderly people, which should be considered for an age-adapted specific management of congestive heart failure in this patient-group.

Aged↗